

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>  
June 14, 2024

### Notice of Listing on the Growth Market of the Tokyo Stock Exchange

Kanagawa, Japan,  
June 14, 2024 – Chordia Therapeutics K.K. (Head Office: Fujisawa City, Kanagawa Prefecture; President: Hiroshi Miyake) was newly listed on the Growth Market of the Tokyo Stock Exchange (Securities Code: 190A) on June 14, 2024. We would like to take this opportunity to respectfully report our listing and express our sincere gratitude to all our stakeholders who have supported our company to date for their support and encouragement.



(From left to right: External Director: Akihiko Shimauchi, Kosuke Ishii, President: Hiroshi Miyake, External Director: Yukari Nishikata, Ayuko Hashimoto)

Chordia Therapeutics is a biotech company engaged in research and development of novel therapies for cancers. Professionals who have been involved in drug discovery for many years are working every day to develop new drugs that will play a key role in future cancer treatment, while leveraging their experience and specialized skills in various areas of R&D. The therapeutic drug CTX-712, a CLK inhibitor that is already in the first stage of clinical trials, has an entirely novel and unprecedented mechanism of action that kills cancer cells by altering splicing, and we have confirmed a response in multiple cancer patients in the Japanese Phase 1 clinical study.

With this listing on the TSE Growth Market, we are even more aware of our responsibility as a public company, and all our employees will work together to

---

enhance our corporate value, and we aspire to deliver first-in-class anti-cancer drugs from Japan to patients around the world as soon as possible.

**About Chordia Therapeutics**

Chordia is a clinical stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan, engaged in the research and development of novel therapies for cancers. Chordia's lead asset CLK inhibitor CTX-712 is under Phase 1 clinical study in Japan. CTX-712 potentially targets the vulnerability of cancer and is expected to deliver benefit to patients of various types of cancer. In addition to CTX-712, Chordia is engaged in the research of several preclinical assets, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors.

Established: November 2017  
Address: 26-1, Muraoka-Higashi 2-chome, Fujisawa,  
Kanagawa 251-0012, Japan  
Representative: Hiroshi Miyake, Representative Director  
Website: <https://www.chorditherapeutics.com/en/>

For more information, contact IR Mizobe: [ir@chorditherapeutics.com](mailto:ir@chorditherapeutics.com)